lofexidine
Adjunctive therapy • Brands: Lucemyra
Last reviewed: 2026-02-12
General information
- Class: Adjunctive therapy
- Common US brands: Lucemyra
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2026-02-12
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
Central α2-adrenergic agonist used to mitigate opioid withdrawal symptoms (autonomic hyperactivity, anxiety, GI distress) during abrupt opioid discontinuation; does not treat opioid use disorder itself and does not reduce relapse risk without follow-on care (label/guideline).
Metabolism & Half‑life
- Metabolism: CYP2D6 (primary contributor), CYP1A2, CYP2C19
- Half‑life: Single-dose range 11–13 h; Steady-state range 17–22 h
Therapeutic Drug Monitoring (TDM)
Recommended: No
Monitoring highlights
- —
Sources
- LUCEMYRA (lofexidine hydrochloride) tablets prescribing information — DailyMed (2026)
- The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update — Journal of Addiction Medicine (2020)
- TIP 63: Medications for Opioid Use Disorder — SAMHSA (2021)
- The Role of Lofexidine in Management of Opioid Withdrawal — Pain Therapy (2019)